Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06366750 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Barzolvolimab in Patients With Prurigo Nodularis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion moved earlier from Jun 2026 to Mar 17, 2026v20
  2. Study sites: 79 to 72v19
  3. Trial status: Recruiting to Active, Not Recruitingv18 Show 5 more changesShow less
    • Enrollment target: estimated 120 to confirmed 140
    • Study sites: 80 to 79
    • Primary completion date: Jan 2026 to Jun 2026
    • Study completion date: Jun 2026 to Mar 2027
    • Study description expanded, about 22 words
  4. Study sites: 78 to 80v17
  5. Study sites: 69 to 78v16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 64 to 69v15
  2. Study sites: 58 to 64v14
  3. Study sites: 55 to 58v13
  4. Study sites: 52 to 55v12
  5. Study sites: 50 to 52v11
  6. Study sites: 48 to 50v10
  7. Study sites: 47 to 48v9
  8. Study sites: 22 to 47v8
  9. Study sites: 13 to 22v7
  10. Study sites: 10 to 13v6
  11. Study sites: 6 to 10v5
  12. Study sites: 5 to 6v4
  13. Study sites: 4 to 5v3
  14. Study sites: 2 to 4
    • Start date changed from estimate of Apr 2024 to Apr 12, 2024
    • Study description revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
Trial Details
NCT Number NCT06366750
Lead Sponsor Celldex Therapeutics
Conditions
(from sponsor)		 Prurigo Nodularis
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov